CN101772500A - 作为蛋白质激酶抑制剂的咪唑并吡嗪 - Google Patents

作为蛋白质激酶抑制剂的咪唑并吡嗪 Download PDF

Info

Publication number
CN101772500A
CN101772500A CN200880101960A CN200880101960A CN101772500A CN 101772500 A CN101772500 A CN 101772500A CN 200880101960 A CN200880101960 A CN 200880101960A CN 200880101960 A CN200880101960 A CN 200880101960A CN 101772500 A CN101772500 A CN 101772500A
Authority
CN
China
Prior art keywords
alkyl
compound
heteroaryl
aryl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880101960A
Other languages
English (en)
Chinese (zh)
Inventor
于涛
D·B·贝兰格
A·D·凯拉奇
孟昭洋
J·R·塔加特
S·J·伊斯波兹
A·K·曼达
萧玉玺
B·A·库卡尼
张永琏
P·J·克伦
R·达尔
M·A·西迪昆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40002934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101772500(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN101772500A publication Critical patent/CN101772500A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200880101960A 2007-06-14 2008-06-11 作为蛋白质激酶抑制剂的咪唑并吡嗪 Pending CN101772500A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US94399907P 2007-06-14 2007-06-14
US60/943,999 2007-06-14
US98793207P 2007-11-14 2007-11-14
US60/987,932 2007-11-14
PCT/US2008/007295 WO2008156614A2 (en) 2007-06-14 2008-06-11 Imidazopyrazines as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
CN101772500A true CN101772500A (zh) 2010-07-07

Family

ID=40002934

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880101960A Pending CN101772500A (zh) 2007-06-14 2008-06-11 作为蛋白质激酶抑制剂的咪唑并吡嗪

Country Status (10)

Country Link
EP (1) EP2170892A2 (de)
JP (1) JP2010529195A (de)
CN (1) CN101772500A (de)
AR (1) AR066958A1 (de)
CA (1) CA2690557A1 (de)
CL (1) CL2008001745A1 (de)
MX (1) MX2009013729A (de)
PE (1) PE20090365A1 (de)
TW (1) TW200911811A (de)
WO (1) WO2008156614A2 (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103429591A (zh) * 2010-12-17 2013-12-04 拜耳知识产权有限责任公司 在治疗过度增殖性病症中用作mps-1和tkk抑制剂的6-取代的咪唑并吡嗪
CN103429593A (zh) * 2011-03-17 2013-12-04 霍夫曼-拉罗奇有限公司 咪唑并吡嗪
CN107954977A (zh) * 2017-12-15 2018-04-24 上海鼎雅药物化学科技有限公司 雷替曲塞中间体的合成方法
CN115702156A (zh) * 2021-04-23 2023-02-14 南京明德新药研发有限公司 吡啶酰胺类化合物
CN116715668A (zh) * 2022-03-07 2023-09-08 上海凌达生物医药有限公司 一类含氮杂环类细胞周期抑制剂化合物、制备方法和用途

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1014572B8 (pt) 2009-04-16 2022-07-19 Fundacion Centro Nac De Investigaciones Oncologicas Carlos Iii Imidazopirazinas para uso como inibidores de cinase
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2473041B1 (de) 2009-09-04 2018-03-07 Merck Sharp & Dohme Corp. Modulatoren von zellzyklus-kontrollpunkten und ihre verwendung in kombination mit kontrollpunkt-kinasehemmern
KR101774035B1 (ko) 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
JP5824040B2 (ja) * 2010-06-01 2015-11-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾピラジン
US20130288250A1 (en) * 2010-10-20 2013-10-31 Universite Bordeaux Segalen Signatures of clinical outcome in gastro intestinal stromal tumors and method of treatment of gastrointestinal stromal tumors
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
EP2444084A1 (de) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Verwendung von PI3K Inhibitoren zur Behandlung der Fettleibigkeit
JP2014521595A (ja) 2011-05-25 2014-08-28 ブリストル−マイヤーズ スクイブ カンパニー 抗アポトーシスＢｃｌ阻害剤として有用な置換スルホンアミド
WO2013000924A1 (en) 2011-06-27 2013-01-03 Janssen Pharmaceutica Nv 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES
WO2014001314A1 (en) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
AU2013289284B2 (en) 2012-07-09 2017-03-30 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
LT3466955T (lt) 2014-01-13 2021-02-25 Aurigene Discovery Technologies Limited Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas
EP3105218B1 (de) 2014-02-13 2019-09-25 Incyte Corporation Cyclopropylamine als lsd1-hemmer
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EP3105219B9 (de) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamine als lsd1-hemmer
JP6602779B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Ｌｓｄ１阻害剤としてのシクロプロピルアミン類
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
EP3277689B1 (de) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclische verbindungen als lsd1-hemmer
MY189367A (en) 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
TWI833686B (zh) 2016-04-22 2024-03-01 美商英塞特公司 Lsd1 抑制劑之調配物
EP3548035A4 (de) 2016-11-30 2020-07-22 Case Western Reserve University Kombinationen von 15-pgdh-inhibitoren mit corticosteroiden und/oder tnf-inhibitoren und verwendungen davon
JP2020514323A (ja) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物と方法
EP3600270B1 (de) * 2017-03-31 2023-06-14 Aurigene Oncology Limited Verbindungen und zusammensetzungen zur behandlung von hämatologischen störungen
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
KR102921276B1 (ko) 2018-11-21 2026-02-03 케이스 웨스턴 리저브 유니버시티 단쇄 데히드로게나아제 활성을 조절하는 조성물 및 방법
JP7771084B2 (ja) * 2020-04-29 2025-11-17 エフ． ホフマン－ラ ロシュ アーゲー 抗菌８－フェニルアミノ－３－（ピラゾール－４－イル）イミダゾ［１，２－ａ］ピラジン誘導体
CA3185209A1 (en) * 2020-07-10 2021-01-27 Alyssa WINKLER Gas41 inhibitors and methods of use thereof
EP4319750A4 (de) 2021-04-08 2025-02-26 Curis, Inc. Kombinationstherapien zur behandlung von krebs
WO2024088192A1 (en) * 2022-10-26 2024-05-02 Js Innopharm (Suzhou) Ltd. An aurora a inhibitor for use in treatments of cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
NZ538685A (en) * 2002-09-23 2008-02-29 Schering Corp Imidazopyrazines as cyclin dependent kinase inhibitors
AU2005304473A1 (en) * 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
US20070117804A1 (en) * 2005-11-10 2007-05-24 Schering Corporation Imidazopyrazines as protein kinase inhibitors

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103429591A (zh) * 2010-12-17 2013-12-04 拜耳知识产权有限责任公司 在治疗过度增殖性病症中用作mps-1和tkk抑制剂的6-取代的咪唑并吡嗪
CN103429593A (zh) * 2011-03-17 2013-12-04 霍夫曼-拉罗奇有限公司 咪唑并吡嗪
CN103429593B (zh) * 2011-03-17 2015-09-09 霍夫曼-拉罗奇有限公司 咪唑并吡嗪
CN107954977A (zh) * 2017-12-15 2018-04-24 上海鼎雅药物化学科技有限公司 雷替曲塞中间体的合成方法
CN115702156A (zh) * 2021-04-23 2023-02-14 南京明德新药研发有限公司 吡啶酰胺类化合物
CN116715668A (zh) * 2022-03-07 2023-09-08 上海凌达生物医药有限公司 一类含氮杂环类细胞周期抑制剂化合物、制备方法和用途
WO2023169438A1 (zh) * 2022-03-07 2023-09-14 上海凌达生物医药有限公司 一类含氮杂环类细胞周期抑制剂化合物、制备方法和用途

Also Published As

Publication number Publication date
CL2008001745A1 (es) 2008-12-05
JP2010529195A (ja) 2010-08-26
MX2009013729A (es) 2010-01-25
TW200911811A (en) 2009-03-16
WO2008156614A2 (en) 2008-12-24
EP2170892A2 (de) 2010-04-07
AR066958A1 (es) 2009-09-23
PE20090365A1 (es) 2009-04-04
WO2008156614A3 (en) 2009-02-12
CA2690557A1 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
CN101772500A (zh) 作为蛋白质激酶抑制剂的咪唑并吡嗪
CN101360499B (zh) 吡唑并[1,5-a]嘧啶衍生物在制备抑制蛋白激酶的药物中的用途
JP5109109B2 (ja) サイクリン依存性キナーゼ阻害剤としての新規イミダゾピラジン
CA2624882C (en) Pyrazolopyrimidines as protein kinase inhibitors
EP1931675B1 (de) Pyrazolo[1, 5a]pyrimidine als proteinkinaseinhibitoren
CN101573363B (zh) 作为细胞周期蛋白依赖性激酶抑制剂的新颖的吡唑并嘧啶
CN101370811A (zh) 作为蛋白激酶抑制剂的咪唑并吡嗪化合物
US20070105864A1 (en) Methods for inhibiting protein kinases
CN101589045A (zh) 作为蛋白质激酶抑制剂的咪唑并吡嗪
CN101516883A (zh) 作为蛋白激酶抑制剂的咪唑并吡嗪化合物
CN101541804A (zh) 作为细胞周期素依赖性激酶抑制剂的吡唑并嘧啶
CN101321757A (zh) 用于治疗癌症的依赖细胞周期蛋白的激酶抑制剂吡唑并嘧啶化合物
CN101970440A (zh) 作为蛋白激酶抑制剂的2-氟吡唑并[1，5-a]嘧啶类
CN101316848A (zh) 用作细胞周期蛋白依赖性激酶抑制剂的新的吡唑并嘧啶化合物
CN101321759A (zh) 作为蛋白激酶抑制剂的吡唑并嘧啶化合物
AU2006302435B2 (en) Use of pyrazolo [1 , 5 -a] pyrimidine derivatives for inhibiting protein kinases methods for inhibiting protein kinases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100707